Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study

[1]  A. Hillmer,et al.  Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing , 2020, Scientific Reports.

[2]  R. Ferris,et al.  Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Edward S. Kim,et al.  Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer , 2020, JAMA oncology.

[4]  P. Baas,et al.  Immunotherapy in Malignant Pleural Mesothelioma , 2020, Frontiers in Oncology.

[5]  K. Takayama,et al.  Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer , 2019, Journal of clinical medicine.

[6]  T. Mio,et al.  Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody , 2019, Thoracic cancer.

[7]  A. Drilon,et al.  Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. , 2019, The Lancet. Oncology.

[8]  A. Ribas,et al.  Tumour-intrinsic resistance to immune checkpoint blockade , 2019, Nature Reviews Immunology.

[9]  David C. Smith,et al.  Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab , 2019, JAMA oncology.

[10]  J. Larkin,et al.  Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. , 2019, The Lancet. Oncology.

[11]  J. Wolchok,et al.  Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. , 2019 .

[12]  P. Baas,et al.  Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. , 2019, The Lancet. Respiratory medicine.

[13]  S. Lantuejoul,et al.  Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. , 2019, The Lancet. Oncology.

[14]  J. Soria,et al.  Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. , 2018, European journal of cancer.

[15]  R. Porcher,et al.  An Alternative Approach for the Analysis of Time‐to‐Event and Survival Outcomes in Pulmonary Medicine , 2018, American journal of respiratory and critical care medicine.

[16]  S. Nomura,et al.  Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer , 2018, Oncotarget.

[17]  A. D’Incecco,et al.  Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. , 2018, The Lancet. Respiratory medicine.

[18]  Paolo A Ascierto,et al.  Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. , 2018, Cancer cell.

[19]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[20]  A. Otsuka,et al.  Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab , 2017, Cancer Chemotherapy and Pharmacology.

[21]  A. D’Incecco,et al.  Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences. , 2017, Cytokine & growth factor reviews.

[22]  Olivier Molinier,et al.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.

[23]  J. V. van Meerbeeck,et al.  Second line therapy in malignant pleural mesothelioma: A systematic review. , 2015, Lung cancer.

[24]  M. Maio,et al.  Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. , 2015, The Lancet. Respiratory medicine.

[25]  P. Ascierto,et al.  Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy , 2014, British Journal of Cancer.

[26]  M. Maio,et al.  Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. , 2013, The Lancet. Oncology.

[27]  Eun‐Kee Park,et al.  Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. , 2011, Bulletin of the World Health Organization.

[28]  M. Byrne,et al.  Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.